Drug intelligence / Profile preview

TJC0265

Development stage: Unknown
Lead developer: TaiwanJ Pharmaceuticals
Modality: Small Molecules

Overview

TJC0265 is a small molecule autotaxin (ATX) inhibitor developed by TaiwanJ Pharmaceuticals. It is designed to treat chronic organ inflammation and fibrotic conditions by reducing the production of lysophosphatidic acid (LPA), a bioactive lipid mediator that drives inflammatory and fibrotic signaling through specific G protein-coupled receptors. By inhibiting the enzymatic activity of autotaxin (also known as ectonucleotide pyrophosphatase/phosphodiesterase 2), TJC0265 disrupts the conversion of lysophosphatidylcholine into LPA. The drug is currently in Phase 1 clinical development, with a primary focus on kidney-related pathological injury (KPI) and other inflammatory indications.

Targets

ENPP2 (Ectonucleotide pyrophosphatase/phosphodiesterase family member 2)

Beyond the preview

Go deeper on TJC0265.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TJC0265.

Explore the full profile